Brought to you by:

Hey, welcome to today's Bay Area Times daily newsletter. If you haven't yet already, follow us on Twitter and on Threads!

Top stories today:
1. Alzheimer's: Lilly's drug slows disease by 35% in early-stage patients
2. U.S. plans to restrict some technology investments in China
3. Microsoft granted 2-month trial pause to negotiate Activision deal with UK
4. Threads announces rate limits, citing spam

0. Data and calendar

All values as of 6 AM ET / 3 AM PT, other than S&P500 close (4 PM ET / 1 PM PT).

All times are ET.

1. Lilly's donanemab slows Alzheimer's by 35% in early-stage patients

Lilly's paper on donanemab's Phase 3 clinical trial.

Lilly's donanemab slows Alzheimer's by 35% in early-stage patients

0. Data and calendar

1. Lilly's donanemab slows Alzheimer's by 35% in early-stage patients

Keep reading

Alibaba’s Qwen3.8 Max 2.4T AI model debuts in preview, trails only Anthropic’s Fable 5

Kimi K3 debuts as world’s largest open AI model from China, closing in on U.S. rivals

Thinking Machines debuts Inkling, top U.S. open-weight AI model

OpenAI’s first device said to be movable, screen-free AI companion speaker

Lilly's donanemab slows Alzheimer's by 35% in early-stage patients

0. Data and calendar

1. Lilly's donanemab slows Alzheimer's by 35% in early-stage patients

Subscribe to keep reading

Keep reading

Alibaba’s Qwen3.8 Max 2.4T AI model debuts in preview, trails only Anthropic’s Fable 5

Kimi K3 debuts as world’s largest open AI model from China, closing in on U.S. rivals

Thinking Machines debuts Inkling, top U.S. open-weight AI model

OpenAI’s first device said to be movable, screen-free AI companion speaker